C-Pharma, Inc.

C-Pharma, Inc. (C-Pharma), is a publicly held biotechnology company that is engaged in the development and commercialization of therapeutic and preventative products for the treatment of hepatitis C virus ("HCV"). The company about to complete its virus-like particles (VLP) technology, vaccine Phase I study, as well as to out-license this vaccine to major pharma companies which uses the virus-like particle (VLP) technology from the NIH. Its product line includes C-Virgin, C-Pegferon, C-Vaxin and C-Immune. C-Pharma was formerly known as Cyplasin Biomedical, Ltd. (CBL). In 2009, the company entered into an irrevocable Letter of Intent (LOI), with Virionics Corporation, for a reverse take over of 100% of the company. C-Pharma is headquartered at Edmonton in Alberta, Canada.

Street: 
9650 - 20 Avenue
City: 
Edmonton
Postcode: 
T6N 1G1
Federal State : 
Canada
Fax: 
1-780-6697633

Company Index Score

Current Index Score Historical Index Score
  • C-Pharma, Inc. currently scores 50 % in the index.
  • C-Pharma, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • C-Pharma, Inc. is currently ranked 1 out of 4535 companies. This is in the top 0.022 % percent of Pharmaceutical companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets